Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity
Journal of Diabetes Research · 2024-01 · 2024 (1)
DOI: 10.1155/jdr/8559677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, online erschienen am 19.12.2024. Verfasst von Chunmei Geng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Metabolomics, Coronary Disease, Biomarkers, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China International Medical Foundation, Taishan Scholar Project of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background and Aims: Coronary heart disease (CHD), hypertension (HTN), depression (Dep), and Type 2 diabetes mellitus (T2DM) are often comorbid, resulting in an exacerbated patient condition and worsened prognosis. A lack of systematic metabolomic studies on comorbidities of CHD remains. Therefore, comprehensive metabolomic‐based evaluation of comorbidities of CHD is necessary. Methods and Results: In the current study, 169 healthy subjects, 149 CHD subjects, 107 CHD + HTN subjects, 126 CHD + Dep subjects, and 58 CHD + T2DM subjects were recruited. Gas chromatography–mass spectrometry was used for metabolite determination, and multivariate statistical analysis was conducted to identify metabolites that are differentially expressed with the comorbidities of CHD. There were 9, 16, 14, and 10 metabolites identified in the healthy and CHD group, the CHD and CHD + HTN group, the CHD and CHD + Dep group, and the CHD and CHD + T2DM group, respectively. Six metabolic pathways were affected, involving starch and sucrose metabolism; fructose and mannose metabolism; citrate cycle; alanine, aspartate, and glutamate metabolism; fatty acid biosynthesis; and glycolysis. Conclusion: Our study has systematically elucidated the metabolic changes underlying the comorbidities of CHD, thereby providing insight into the mechanisms associated with these alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
- Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Translational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
- Department of Neurosurgery, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
- Department of Endocrinology, Tengzhou Central People's Hospital, Tengzhou, Shandong, China.
ORCID-Profile: Chunmei Geng, Benhui Liang, Zihan Kong, Lei Feng, Jianhua Wang, Qingying Si, Pei Jiang
Förderung
- China International Medical Foundation
- Taishan Scholar Project of Shandong Province
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Geng, C., Liang, B., Kong, Z., Feng, L., Wang, J., Si, Q., & Jiang, P. (2024). Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity. Journal of Diabetes Research, 2024(1). https://doi.org/10.1155/jdr/8559677
Vancouver
Geng C, Liang B, Kong Z, Feng L, Wang J, Si Q, et al. Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity. Journal of Diabetes Research. 2024;2024(1). doi:10.1155/jdr/8559677
BibTeX
@article{Geng2024,
author = {Geng, Chunmei and Liang, Benhui and Kong, Zihan and Feng, Lei and Wang, Jianhua and Si, Qingying and Jiang, Pei},
title = {Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity},
journal = {Journal of Diabetes Research},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/jdr/8559677}
}
EUVIMED